Arun Azad

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2019 · 1.1K citations · Full text

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1K citations

Urology, Oncology, Genitourinary Cancer +7

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala, Gillian Vandekerkhove, Daniel Khalaf et al. · Cancer Discovery · 2018 · 507 citations · Full text

Pathology, Rapid Resistance, Invasive Biomarkers +17

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Arun Azad, Stanislav Volik, Alexander W. Wyatt et al. · Clinical Cancer Research · 2015 · 466 citations

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 453 citations

Urology, Medicine, Pharmacology +5